Poseida Therapeutics Inc (PSTX)
2.99
+0.09
(+3.10%)
USD |
NASDAQ |
May 31, 16:00
2.97
-0.02
(-0.67%)
After-Hours: 20:00
Poseida Therapeutics Cash from Operations (TTM): -69.30M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -69.30M |
December 31, 2023 | -92.17M |
September 30, 2023 | -61.02M |
June 30, 2023 | -7.03M |
March 31, 2023 | -13.45M |
December 31, 2022 | -26.77M |
September 30, 2022 | -20.70M |
June 30, 2022 | -123.45M |
March 31, 2022 | -114.81M |
Date | Value |
---|---|
December 31, 2021 | -102.54M |
September 30, 2021 | -141.33M |
June 30, 2021 | -129.79M |
March 31, 2021 | -129.50M |
December 31, 2020 | -113.33M |
September 30, 2020 | -99.58M |
June 30, 2020 | -89.42M |
March 31, 2020 | -72.74M |
December 31, 2019 | -64.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-141.33M
Minimum
Sep 2021
-7.03M
Maximum
Jun 2023
-81.75M
Average
-90.79M
Median
Cash from Operations (TTM) Benchmarks
Biomea Fusion Inc | -104.58M |
Cartesian Therapeutics Inc | -58.31M |
Lantern Pharma Inc | -13.66M |
NovaBay Pharmaceuticals Inc | -4.516M |
Palatin Technologies Inc | -33.74M |